Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects
Status:
Completed
Trial end date:
2020-11-26
Target enrollment:
Participant gender:
Summary
Psilocybin is a classic serotonergic hallucinogen acting on the 5-HT2A receptor. It is used
recreationally and in psychiatric research. Selective serotonin reuptake inhibitors (SSRIs)
like escitalopram are first-line treatments for depression. They inhibit the serotonin
transporter (SERT). This might cause a possible downregulation of postsynaptic 5-HT
receptors, e.g. the 5-HT2A receptor. The aim of the study is to investigate the effects of
psilocybin after escitalopram and Placebo pretreatment. Subjective and physiological effects
as well as effects on gene expression will be assessed.